Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Karamchandani DM, Gonzalez RS, Westerhoff M, Westbrook LM, Panarelli NC, Al-Nuaimi M, et al. Measuring depth of invasion of submucosa - invasive adenocarcinoma in oesophageal endoscopic specimens: how good are we? Histopathology. 2022;80(2):420-429.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, et al. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022;15(1):3-10.

Lubetzky M, Zhao Z, Sukhu A, Sharma V, Sultan S, Kapur Z, et al. Characteristics of natural immunity to SARS-CoV-2 over time in wait-listed dialysis patients and recent kidney transplant recipients. Nephrol Dial Transplant. 2022;37(8):1585-1587.

Rodino KG, Peaper DR, Kelly BJ, Bushman F, Marques A, Adhikari H, et al. Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1. medRxiv. 2022.

Fowler FC, Chen B-, Zolnerowich N, Wu W, Pavani R, Paiano J, et al. DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells. Elife. 2022;11.

Greenberg J, Limberg J, Verma A, Kim D, Chen X, Lee YJ, et al. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. JCI Insight. 2022;7(23).

Kim S, Au CM, Bin Jamalruddin MA, Abou-Ghali NE, Mukhtar E, Portella L, et al. AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. Elife. 2022;11.

Nassar AH, Adib E, Alaiwi SA, Zarif TE, Groha S, Akl EW, et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022;40(10):1161-1172.e5.

Lebowitz E, Kim JS, Magro C. Reactive arthritis following COVID-19 vaccination with BNT162b2. JAAD Case Rep. 2022;24:108-111.